Michael Polydefkis | Academic Influence

Michael Polydefkis's AcademicInfluence.com Rankings

Michael Polydefkis

Computer Science

#11615

World Rank

#12327

Historical Rank

Computational Linguistics

#2984

World Rank

#3018

Historical Rank

Machine Learning

#5419

World Rank

#5490

Historical Rank

Artificial Intelligence

#5848

World Rank

#5937

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Michael Polydefkis's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Michael Polydefkis Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael James Polydefkis is an American neurologist. He is a Professor of Neurology at Johns Hopkins University School of Medicine and Co-Director of the Cutaneous Nerve Laboratory. Polydefkis research focuses on treating hATTR amyloidosis and diabetic and HIV-associated peripheral neuropathy.

(See a Problem?)

Michael Polydefkis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis (2018) (1423)
The spectrum of neuropathy in diabetes and impaired glucose tolerance (2003) (682)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society (2010) (653)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis (2018) (553)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society (2010) (511)
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. (2004) (340)
Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) (2009) (311)
Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy (2002) (278)
Subclinical sensory neuropathy in late-onset restless legs syndrome (2000) (265)
Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review) (2009) (242)
Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy (2008) (163)
Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role of Autonomic Testing, Nerve Biopsy, and Skin Biopsy (An Evidence‐Based Review) (2009) (161)
Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. (1990) (145)
Assessment of Epidermal Nerve Fibers: A New Diagnostic and Predictive Tool for Peripheral Neuropathies (2007) (129)
New insights into diabetic polyneuropathy. (2003) (127)
Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role of Laboratory and Genetic Testing (An Evidence‐Based Review) (2009) (125)
Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations (2015) (116)
Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. (2007) (115)
The utility of skin biopsy for prediction of progression in suspected small fiber neuropathy (2006) (112)
The Incidence of, Risk Factors for, and Sequelae of Herpes Zoster Among HIV Patients in the Highly Active Antiretroviral Therapy Era (2005) (111)
The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations. (2017) (108)
Skin biopsy as a tool to assess distal small fiber innervation in diabetic neuropathy. (2001) (101)
Longitudinal assessment of oxaliplatin-induced neuropathy (2011) (100)
Evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence‐based review) (2009) (100)
Pathology and Quantitation of Cutaneous Innervation (2005) (97)
Epidermal reinnervation after intracutaneous axotomy in man (2003) (87)
Enzyme replacement therapy and intraepidermal innervation density in Fabry disease (2006) (80)
Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy. (2011) (79)
Longitudinal Assessment of Small Fiber Neuropathy: Evidence of a Non-Length-Dependent Distal Axonopathy. (2016) (77)
Assessment of cutaneous innervation by skin biopsies (2001) (71)
Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence‐based review) (2009) (70)
Herpes Zoster Among Persons Living With HIV in the Current Antiretroviral Therapy Era (2012) (64)
Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies (2009) (54)
Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy (2017) (51)
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition (1990) (50)
Chronic non-freezing cold injury results in neuropathic pain due to a sensory neuropathy (2017) (47)
Peripheral nerve toxic effects of nitrofurantoin. (2012) (45)
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study (2020) (45)
Impaired reinnervation in HIV infection following experimental denervation (2007) (44)
Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. (2018) (43)
Characterization of Vestibulopathy in Individuals with Type 2 Diabetes Mellitus (2015) (42)
Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. (2007) (41)
Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial (2017) (38)
Monocarboxylate transporter 1 in Schwann cells contributes to maintenance of sensory nerve myelination during aging (2020) (38)
Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial (2020) (34)
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7 (2019) (32)
LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection (2018) (30)
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients (2014) (30)
Factors influencing nerve regeneration in a trial of timcodar dimesylate (2006) (28)
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial (2022) (28)
Monocyte Traffic, Dorsal Root Ganglion Histopathology, and Loss of Intraepidermal Nerve Fiber Density in SIV Peripheral Neuropathy. (2015) (27)
Collateral sprouting of human epidermal nerve fibers following intracutaneous axotomy (2006) (26)
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (2019) (26)
Structural and functional characterization of nerve fibres in polyneuropathy and healthy subjects (2016) (25)
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis (2020) (25)
Factors influencing sweat gland innervation in diabetes (2015) (23)
Structural and functional assessment of skin nerve fibres in small‐fibre pathology (2015) (21)
Safety and efficacy of ranirestat in patients with mild‐to‐moderate diabetic sensorimotor polyneuropathy (2015) (20)
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy (2018) (20)
Peripheral neuropathic changes in pachyonychia congenita (2016) (20)
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis (2019) (17)
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial (2018) (17)
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis (2020) (16)
Idiopathic distal sensory polyneuropathy (2020) (16)
Sensory and autonomic function and structure in footpads of a diabetic mouse model (2017) (15)
Author Correction: LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection (2018) (15)
Loss of intraepidermal nerve fiber density during SIV peripheral neuropathy is mediated by monocyte activation and elevated monocyte chemotactic proteins (2015) (15)
Use of Skin Biopsy in the Diagnosis of Small Fibre Neuropathy (2010) (15)
Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma (2016) (14)
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey (2021) (14)
What can we learn from failed neuropathic pain trials? (2008) (13)
SIV-induced impairment of neurovascular repair: a potential role for VEGF (2012) (13)
Cutaneous Collateral Axonal Sprouting Re-Innervates the Skin Component and Restores Sensation of Denervated Swine Osteomyocutaneous Alloflaps (2013) (12)
Epidermal innervation in diabetes. (2014) (12)
PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY (2017) (12)
Ghrelin agonist HM01 attenuates chemotherapy‐induced neurotoxicity in rodent models (2018) (12)
Skin biopsy–proven flecainide‐induced neuropathy (2012) (11)
Effect of diabetes type on long‐term outcome of epidermal axon regeneration (2019) (11)
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression (2021) (11)
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients (2020) (11)
Skin biopsy findings predict development of symptomatic neuropathy in patients with HIV (2006) (10)
Sweat Gland Denervation in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome (CANVAS) (2017) (10)
Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies (2011) (9)
Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations (2021) (9)
The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. (2020) (9)
APOE ε4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy (2005) (9)
Epidermal innervation as a tool to study human axonal regeneration and disease progression (2017) (8)
APOE epsilon4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy. (2005) (8)
The lateral thoracic nerve and the cutaneous maximus muscle—A novel in vivo model system for nerve degeneration and regeneration studies (2012) (8)
Pain mechanisms in hereditary palmoplantar keratodermas (2019) (8)
Nociceptin/orphanin FQ opioid peptide‐receptor expression in pachyonychia congenita (2018) (7)
Reducing monocarboxylate transporter MCT1 worsens experimental diabetic peripheral neuropathy (2020) (7)
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis (2020) (6)
Neuropathic symptoms with SARS-CoV-2 vaccination (2022) (5)
Oligonucleotide Drugs for Transthyretin Amyloidosis. (2018) (5)
An oral form of methylglyoxal-bis-guanylhydrazone reduces monocyte activation and traffic to the dorsal root ganglia in a primate model of HIV-peripheral neuropathy (2017) (5)
Acroosteolysis in Diabetes Mellitus (2012) (5)
Monocarboxylate transporter 1 in Schwann cells is critical for maintenance of sensory nerve myelination during aging (2019) (4)
HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (2022) (4)
Ethoxyquin is neuroprotective and partially prevents somatic and autonomic neuropathy in db/db mouse model of type 2 diabetes (2021) (4)
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) (2022) (4)
Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (2016) (3)
HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (2021) (3)
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis (2020) (3)
Peripheral neuropathy and HIV. (2002) (3)
Herpes Zoster among Persons Living with HIV in the Current ART Era (2012) (3)
P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study (2019) (3)
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update (2022) (2)
Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis (2019) (2)
Impact of Patisiran on overall health status in hATTR amyloidosis : Results from the APOLLO trial (2018) (2)
Mycobacterium leprae induces Schwann cell proliferation and migration in a denervated milieu following intracutaneous excision axotomy in nine-banded armadillos (2022) (2)
Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis (2018) (2)
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update (2022) (2)
Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324) (2018) (2)
Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy (2021) (2)
Infusion related reactions in patients with hATTR amyloidosis treated with patisiran (2018) (2)
Mnis+7 And Lower Limb Function In Inotersen Treatment Of Hattr. (2020) (2)
Punch Skin Biopsy in Diabetic Neuropathy (2007) (2)
PS1221 LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE (2019) (1)
Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis : Global OLE Study (2020) (1)
EFFECT OF PATISIRAN ON NERVE FIBER DENSITY AND AMYLOID CONTENT IN SKIN : RESULTS FROM PHASE 2 OPEN LABEL EXTENSION (OLE) STUDY IN HATTR AMYLOIDOSIS (2017) (1)
Global open-label extension: 24-month data of patisiran in patients with HATTR amyloidosis (2021) (1)
Inotersen Improves Quality of Life and Neuropathy in Patients with Hereditary Transthyretin (HATTR) Amyloidosis with Polyneuropathy: Results of the Phase 3 Study Neuro-TTR (2018) (1)
Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (2020) (1)
Chapter 13 Peripheral Neuropathy Treatment Trials (2001) (1)
Burden of Hereditary Transthyretin Amyloidosis With Polyneuropathy in Patients Enrolled in the Phase 3 Study NEURO-TTR (P1.331) (2018) (1)
LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection (2018) (1)
Plasma proteome analysis of patients with hereditary transthyretin-mediated (hATTR) amyloidosis establishes neurofilament light chain (NfL) as a biomarker of disease and treatment response (2019) (1)
Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy” (2019) (0)
Peripheral nerve safety measures in a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study of fulranumab in patients with painful diabetic neuropathy (2013) (0)
Loss of intraepidermal nerve fiber density during SIV peripheral neuropathy is mediated by monocyte activation and elevated monocyte chemotactic proteins (2015) (0)
Reply: Non-freezing cold injury: a multi-faceted syndrome. (2018) (0)
Peripheral Neuropathy: No Longer the Land of Therapeutic Nihilism (2021) (0)
Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006) (2018) (0)
Neurologic Involvement in Val-122 Ile Familial Amyloidosis (P1.026) (2014) (0)
Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis (2023) (0)
SIV-induced impairment of neurovascular repair: a potential role for VEGF (2012) (0)
How a Drug is Assessed Once It ’ s in Clinical Trials : A Perspective from a Clinical Pharmacology Reviewer (2018) (0)
Restless Legs Syndrome in Neurological Disorders (2009) (0)
Author Correction: LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection (2018) (0)
P-48 Neurofilament light chain as a biomarker in hereditary transthyretin-mediated amyloidosis: 36-month data from the patisiran global open-label extension (2023) (0)
NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy (S14.001) (2023) (0)
Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001) (2018) (0)
Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary TransthyretinMediated (hATTR) Amyloidosis: Patisiran Global OLE Study (2021) (0)
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (2020) (0)
A 73-year-old woman with chronic pelvic pain, burning toes, and an eighty-pound weight loss. (2008) (0)
856 Peripheral neuropathic changes in prurigo nodularis (2022) (0)
Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update (S27.008) (2019) (0)
Abstract P19: CUTANEOUS COLLATERAL AXONAL SPROUTING RE-INNERVATES THE SKIN COMPONENT AND RESTORES SENSATION OF DENERVATED SWINE OSTEOMYOCUTANEOUS ALLOFLAPS (2013) (0)
Editorial Board (2007) (0)
LONG-TERM, INTEGRATED CARDIAC SAFETY OF PATISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (2020) (0)
Can skin biopsy be used to evaluate demyelinating neuropathies? (2005) (0)
Correction to: Peripheral Neuropathy: No Longer the Land of Therapeutic Nihilism (2022) (0)
Effect of Ixabepilone Chemotherapy on Cutaneous Sensory Fibers and Mitochondria in Breast Cancer Patients (2014) (0)
Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study (S14.003) (2023) (0)
Skin biopsy appearance in nitrofurantoin neurotoxicity (2011) (0)
Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis (2021) (0)
Risk Factors for Mortality in Patients with Hereditary Transthyretin-Mediated Amyloidosis: An Analysis of APOLLO and Global Open Label Extension Studies (2019) (0)
An oral form of methylglyoxal-bis-guanylhydrazone reduces monocyte activation and traffic to the dorsal root ganglia in a primate model of HIV-peripheral neuropathy (2017) (0)
Characterization of small nerve fibers in painful distal symmetric polyneuropathy and healthy controls (2015) (0)
EuropeanFederationofNeurologicalSocieties/PeripheralNerve SocietyGuidelineontheuseofskinbiopsyinthediagnosisofsmall fiberneuropathy.ReportofajointtaskforceoftheEuropeanFe- derationofNeurologicalSocietiesandthePeripheralNerveSociety (2010) (0)
Large Pleural Effusion: A Pitfall in the Quantitation of 99mTc-PYP Imaging for ATTR Cardiac Amyloidosis. (2022) (0)

This paper list is powered by the following services:

Other Resources About Michael Polydefkis

en.wikipedia.org

What Schools Are Affiliated With Michael Polydefkis?

Michael Polydefkis is affiliated with the following schools: